| A common polymorphism acts as an intragenic modifier of mutant p53 behaviour MC Marin, CA Jost, LA Brooks, MS Irwin, J O'Nions, JA Tidy, N James, ... Nature genetics 25 (1), 47-54, 2000 | 649 | 2000 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 533 | 2018 |
| Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ... Annals of Oncology 30 (12), 1992-2003, 2019 | 430 | 2019 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 395 | 2020 |
| Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? GJ Wehner, L Jing, CM Haggerty, JD Suever, JB Leader, DN Hartzel, ... European heart journal 41 (12), 1249-1257, 2020 | 264 | 2020 |
| A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen S Culine, C Theodore, M De Santis, B Bui, T Demkow, J Lorenz, ... British Journal of Cancer 94 (10), 1395-1401, 2006 | 223 | 2006 |
| A study of information seeking by cancer patients and their carers N James, H Daniels, R Rahman, C McConkey, J Derry, A Young Clinical oncology 19 (5), 356-362, 2007 | 211 | 2007 |
| Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to … DE Neal, C Metcalfe, JL Donovan, JA Lane, M Davis, GJ Young, ... European urology 77 (3), 320-330, 2020 | 171 | 2020 |
| Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials A Choudhury, N Porta, E Hall, YP Song, R Owen, R MacKay, CML West, ... The lancet oncology 22 (2), 246-255, 2021 | 154 | 2021 |
| Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate‐pulsed cells: a phase I/II study HS Pandha, RJ John, J Hutchinson, N James, M Whelan, C Corbishley, ... BJU international 94 (3), 412-418, 2004 | 135 | 2004 |
| Muscle-invasive and metastatic bladder cancer JA Witjes, E Compérat, NC Cowan, M De Santis, G Gakis, N James, ... Eur Urol Guidel 71 (3), 462-475, 2015 | 120 | 2015 |
| Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021 S Gillessen, A Armstrong, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, ... European urology 82 (1), 115-141, 2022 | 94 | 2022 |
| What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis CL Vale, DJ Fisher, IR White, JR Carpenter, S Burdett, NW Clarke, ... Annals of Oncology 29 (5), 1249-1257, 2018 | 88 | 2018 |
| The development of intermediate clinical endpoints in cancer of the prostate (ICECaP) ICECaP Working Group Journal of the National Cancer Institute 107 (12), djv261, 2015 | 85 | 2015 |
| Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and … A Lane, C Metcalfe, GJ Young, TJ Peters, J Blazeby, KNL Avery, ... BJU international 118 (6), 869-879, 2016 | 75 | 2016 |
| Morgan, John A FM Andrews, N James Sonquist, and Laura Klem, 1973 | 75 | 1973 |
| Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study) JA Lane, JL Donovan, GJ Young, M Davis, EI Walsh, KNL Avery, ... BJU international 130 (3), 370-380, 2022 | 68 | 2022 |
| The West Midlands bladder cancer prognosis programme: rationale and design MP Zeegers, RT Bryan, C Langford, L Billingham, P Murray, ... BJU international 105 (6), 784-788, 2010 | 62 | 2010 |
| Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform S Gillessen, C Gilson, N James, A Adler, MR Sydes, N Clarke European urology 70 (6), 906-908, 2016 | 60 | 2016 |
| Infant speech recognition in multisyllabic contexts JV Goodsitt, PA Morse, N James, V Hoeve, N Cowan Child Development, 903-910, 1984 | 54 | 1984 |
